Table 3.
Therapy and outcomes in patients with anti-factor H associated hemolytic uremic syndrome.
| Variable | 2007-12 (n = 119) | 2013-18 (n = 317) | Whole cohort (n = 436) | P |
|---|---|---|---|---|
| Dialysis requirement (%) | 101 (84.9) | 236 (74.4) | 337 (77.3) | 0.021 |
| Duration of dialysis, days | 26 (10–57) | 13 (5.8–30.3) | 15 (6–36) | < 0.001 |
| Plasma exchange (PEX, %) | 91 (76.5) | 247 (77.9) | 338 (77.5) | 0.75 |
| Days to PEX | 17 (7–32) | 11 (6–22) | 12 (6–24) | 0.011 |
| Induction immunosuppression (%) | 79 (66.4) | 243 (76.7) | 322 (73.9) | 0.029 |
| Maintenance immunosuppression (%) | 50 (42) | 139 (43.8) | 189 (43.3) | 0.73 |
| Days to immunosuppression | 34 (20–53) | 21 (11–31.8) | 27 (12–35) | < 0.001 |
| Onset to hematological remission, days | 38 (22.5–54.3) | 24 (16–35) | 27 (17–41) | < 0.001 |
| Outcome at 3-months | N = 105 | N = 251 | N = 356 | |
| Stage 2 HTN or proteinuria ≥2+ | 48 (45.7) | 104 (41.4) | 152 (42.7) | 0.46 |
| CKD stages 2–3 | 18 (17.1) | 46 (18.3) | 64 (18.0) | 0.79 |
| Adverse outcome CKD stage 4–5; death | 35 (33.3) | 46 (18.3) | 81 (22.8) | 0.002 |
| Outcome at last follow-up | N = 105 | N = 251 | N = 356 | |
| Stage 2 HTN or proteinuria ≥2+ | 31 (26.1) | 64 (20.2) | 95 (26.7) | 0.43 |
| CKD stages 2–3 | 12 (10.1) | 27 (8.5) | 39 (11.0) | 0.86 |
| Adverse outcome CKD stage 4–5; death | 38 (36.2) | 53 (21.1) | 91 (25.6) | 0.003 |
| Relapse | 26 (24.7) | 35 (13.9) | 61 (17.1) | 0.003 |
Data shown as median (interquartile range) or N (%); CKD, chronic kidney disease; HTN, hypertension; PEX, plasma exchange.